Drug Profile
Research programme: antiangiogenic therapeutics - Exonate
Alternative Names: EXN 169; Serine/threonine-protein kinase 1 inhibitors; SPHINXes; SRPK1 inhibitorsLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Exonate
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors; Protein-serine-threonine kinase inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in United Kingdom (Topical, Drops)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in United Kingdom (Topical, Drops)